You are viewing the site in preview mode

Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer

Fig. 2

Guadecitabine slows tumor growth and immediately reverses the rapidly expanding myeloid population. a Timecourse experiment showing 4 T1 tumor growth in WT balb/c mice. Total cellularity and number of MDSCs from b spleen, c bone marrow, and d blood. Arrows indicate guadecitabine treatments; dotted line indicates naïve levels. Significance determined using ANOVA with Sidak’s multiple comparison tests. Error bars represent SD. ns = not significant, *:p value< 0.0332; **:p value< 0.0021; ***:p value< 0.0002; ****:p value< 0.00001

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us